See the DrugPatentWatch profile for stiripentol

Stiripentol, a drug used to treat Dravet syndrome, has been suggested to potentially reduce the need for fenfluramine in managing seizures [1]. Stiripentol is known to enhance gamma-aminobutyric acid (GABA) transmission in the brain, which helps to regulate excitability and reduce the likelihood of seizures [1][2].

Fenfluramine, on the other hand, is a drug that has been used off-label to treat seizures in Dravet syndrome, although it carries the risk of causing valvular heart disease and pulmonary hypertension [1][3]. Therefore, reducing the need for fenfluramine by using stiripentol could potentially minimize these risks.

While there is some evidence to suggest that stiripentol may reduce the need for fenfluramine, more research is needed to fully understand the potential benefits and risks of this approach [1]. It is important for healthcare providers to carefully consider the individual needs and circumstances of each patient when making treatment decisions.

In summary, stiripentol's role in enhancing GABAergic transmission may reduce the need for fenfluramine in managing seizures, but more research is needed to confirm this potential benefit.

Sources:

1. "[Stiripentol for Dravet Syndrome](https://www.drugpatentwatch.com/drugs/stiripentol)"
2. "[Stiripentol: A Review in Dravet Syndrome](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6146053/)"
3. "[Fenfluramine for Dravet Syndrome](https://www.drugpatentwatch.com/drugs/fenfluramine)"